Resveratrol inhibits proliferation and promotes apoptosis via the androgen receptor splicing variant 7 and PI3K/AKT signaling pathway in LNCaP prostate cancer cells

Ye,Mushi; Tian,Huanshu; Lin,Shanhong; Mo,Jierong; Li,Zhuo; Chen,Xiaojun; Liu,Jianjun

doi:10.3892/ol.2020.12032

Resveratrol inhibits proliferation and promotes apoptosis via the androgen receptor splicing variant 7 and PI3K/AKT signaling pathway in LNCaP prostate cancer cells

Authors:
- Mushi Ye
- Huanshu Tian
- Shanhong Lin
- Jierong Mo
- Zhuo Li
- Xiaojun Chen
- Jianjun Liu
View Affiliations

Affiliations: Laboratory of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000, P.R. China
Published online on: August 27, 2020 https://doi.org/10.3892/ol.2020.12032
Article Number: 169
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a common malignant tumor of the male genitourinary system and its incidence increases with age. Studies have shown that resveratrol (Res) inhibits cancer cell proliferation, migration, invasion and promotes apoptosis. The present study evaluated the effect of Res in two human prostate cancer cell lines (the androgen‑dependent LNCaP cell line and the non‑androgen‑independent LNCaP‑B cell line) on proliferation and apoptosis. A proliferation assay was used to demonstrate that Res inhibited proliferation of LNCaP and LNCaP‑B cells in the range of 25‑100 µM, and the effect was time‑ and dose‑dependent. Using flow cytometry, it was reported that various concentrations of Res induced apoptosis in LNCaP and LNCaP‑B cells, and that the apoptotic effect of Res was dose‑dependent. A chemiluminescence assay showed that Res inhibited prostate specific antigen levels in LNCaP and LNCaP‑B cells. Reverse transcription quantitative‑PCR showed that Res inhibited the expression of androgen receptor (AR) in LNCaP and LNCaP‑B cells at the mRNA level. Western blot analysis showed that Res suppressed the expression of AR protein as well as protein kinase B (AKT) phosphorylation. To study the effect of Res on the expression of AR splicing variant 7 (ARV7) and the PI3K/AKT signaling pathway in prostate cancer cells, as well as the underlying molecular mechanisms, the recombinant ARV7 expression vector Pcdna3.1‑ARV7 was transfected into LNCaP and LNCaP cells and the aforementioned experiments were repeated. It was revealed that Res acted via the ARV7 and the AKT pathways. Taken together, the present results suggested that Res suppresses the proliferation of prostate cancer cells, promotes apoptosis and inhibits the expression of AR mRNA and protein. These effects likely resulted from inhibition of ARV7 and the AKT signaling pathway.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Park JW, Jang WS, Koh DH, Ham WS, Rha KH, Hong SJ and Choi YD: Impact of early salvage androgen deprivation therapy in localized prostate cancer after radical prostatectomy: A propensity score matched analysis. Yonsei Med J. 59:580–587. 2018. View Article : Google Scholar : PubMed/NCBI
3	Sharifi N, Gulley JL and Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA. 294:238–244. 2005. View Article : Google Scholar : PubMed/NCBI
4	Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1–2 study. Lancet. 375:1437–1446. 2010. View Article : Google Scholar : PubMed/NCBI
5	Taneja SS: Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. J Urol. 190:8802013. View Article : Google Scholar
6	Shafi AA, Yen AE and Weigel NL: Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 140:223–238. 2013. View Article : Google Scholar
7	Ryan CJ and Tindall DJ: Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 29:3651–3658. 2011. View Article : Google Scholar : PubMed/NCBI
8	Tilley WD, Buchanan G, Hickey TE and Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res. 2:277–285. 1996.PubMed/NCBI
9	He B, Gampe RJ Jr, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT and Wilson EM: Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell. 16:425–438. 2004. View Article : Google Scholar : PubMed/NCBI
10	Shang Y, Myers M and Brown M: Formation of the androgen receptor transcription complex. Mol Cell. 9:601–610. 2002. View Article : Google Scholar : PubMed/NCBI
11	Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration- resistant tumor growth. Cancer Res. 68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
12	Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA and Visakorpi T: Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69:8141–8149. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 10:33–39. 2004. View Article : Google Scholar : PubMed/NCBI
14	Moradi A, Srinivasan S, Clements J and Batra J: Beyond the biomarker role: Prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev. 38:333–346. 2019. View Article : Google Scholar : PubMed/NCBI
15	Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC and Bevan CL: Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol Endocrinol. 26:1694–1706. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lin CY, Jan YJ, Kuo LK, Wang BJ, Huo C, Jiang SS, Chen SC, Kuo YY, Chang CR and Chuu CP: Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5. Cancer Sci. 109:3564–3574. 2018. View Article : Google Scholar : PubMed/NCBI
17	Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A and Wikström P: Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 6:e190592011. View Article : Google Scholar : PubMed/NCBI
19	Stewart JR, Artime MC and O'Brian CA: Resveratrol: A candidate nutritional substance for prostate cancer prevention. J Nutr. 133 (7 Suppl):2440S–2443S. 2003. View Article : Google Scholar : PubMed/NCBI
20	Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, et al: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70:7392–7399. 2010. View Article : Google Scholar : PubMed/NCBI
21	Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
22	Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB and Bellanger RA: Resveratrol: Potential as anticancer agent. J Diet. (Suppl 9):45–56. 2012. View Article : Google Scholar
23	Delmas D, Lancon A, Colin D, Jannin B and Latruffe N: Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr Drug Targets. 7:423–442. 2006. View Article : Google Scholar : PubMed/NCBI
24	Jang YG, Go RE, Hwang KA and Choi KC: Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway. J Steroid Biochem Mol Biol. 192:1054062019. View Article : Google Scholar : PubMed/NCBI
25	Mitchell SH, Zhu W and Young CY: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 59:5892–5895. 1999.PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, et al: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
28	Sobhani N, Generali D, D'Angelo A, Aieta M and Roviello G: Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest New Drug. 36:1133–1137. 2018. View Article : Google Scholar
29	Deng Y, Bi R, Zhu Z, Li S, Xu B, Rather WA and Wang C: A surveillance, epidemiology and end results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma. Oncol Lett. 18:1057–1070. 2019.PubMed/NCBI
30	Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North S, Rendon R, et al: The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 9:90–96. 2015. View Article : Google Scholar : PubMed/NCBI
31	Penning TM: Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). J Steroid Biochem Mol Biol. 153:105–113. 2015. View Article : Google Scholar : PubMed/NCBI
32	Thakur A, Vaishampayan U and Lum LG: Immunotherapy and immune evasion in prostate cancer. Cancers. 5:569–590. 2013. View Article : Google Scholar : PubMed/NCBI
33	Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220. 1997. View Article : Google Scholar : PubMed/NCBI
34	Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER and Reddy GP: Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res. 62:2488–2492. 2002.PubMed/NCBI
35	Isaacs JT and Isaacs WB: Androgen receptor outwits prostate cancer drugs. Nat Med. 10:26–27. 2004. View Article : Google Scholar : PubMed/NCBI
36	Scher HI and Sawyers CL: Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
37	Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, et al: A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs. 34:112–118. 2005. View Article : Google Scholar
38	Vellky JE, Bauman TM, Ricke EA, Huang W and Ricke WA: Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer. Prostate. 79:1811–1822. 2019. View Article : Google Scholar : PubMed/NCBI
39	Hsu CL, Liu JS, Wu PL, Guan HH, Chen YL, Lin AC, Ting HJ, Pang ST, Yeh SD, Ma WL, et al: Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis. Mol Oncol. 8:1575–1587. 2014. View Article : Google Scholar : PubMed/NCBI
40	Chen H, Zhou L, Wu X, Li R, Wen J, Sha J and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 21:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
41	Liao Y, Grobholz R, Abel U, Trojan L, Michel MS, Angel P and Mayer D: Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer. Int J Cancer. 107:676–680. 2003. View Article : Google Scholar : PubMed/NCBI
42	Pilling AB and Hwang C: Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate. 79:1347–1359. 2019. View Article : Google Scholar : PubMed/NCBI
43	Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY and Chang C: Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem. 278:50902–50907. 2003. View Article : Google Scholar : PubMed/NCBI